Form 4: Cullinane Therapeutics Chief Legal Officer Reports Acquisition of Stock Options and Restricted Stock Units

Jacquelyn L. Sumer, Chief Legal Officer of Cullinan Therapeutics, reports the acquisition of stock options and restricted stock units.

Summary

• On February 19, 2025, Jacquelyn L. Sumer, Chief Legal Officer of Cullinan Therapeutics, Inc., acquired 50,000 shares of common stock and stock options for 100,000 shares.
• The common stock was acquired at a price of $0.
• The stock options have an exercise price of $9.43 and expire on February 19, 2035.
• The shares underlying the restricted stock units vest on an annual basis over four years.
• The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
• Following the transaction, Ms. Sumer directly owns 140,651 shares of common stock and 100,000 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating stock and option grants to an executive, which is a common practice. It doesn't inherently suggest positive or negative implications for the company's performance.

Positives

• The acquisition of stock options and restricted stock units by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedules described are fairly standard, with both annual and monthly vesting periods being common.

Stakeholder Impact

• The acquisition of shares and options by the Chief Legal Officer could be viewed positively by shareholders, as it aligns her interests with the company's success.

Key Dates

Keywords

Cullinan Therapeutics, CGEM, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Beneficial Ownership, Jacquelyn L. Sumer, Chief Legal Officer